Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-01-29
2000-08-22
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 64, A61K 3170
Patent
active
061072850
ABSTRACT:
According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically acceptable salt of an anthracycline glycoside dissolved in a physiologically acceptable solvent therefor, which has not been reconstituted from a lyophilizate and which has a pH of from 2.5 to 6.5. The solution of the invention is particularly advantageous for the administration by injection of the anthracycline glycoside drugs, e.g. doxorubicin, in the treatment of both human and animal tumors.
REFERENCES:
patent: 3590028 (1971-06-01), Arcamone et al.
patent: 3686163 (1972-08-01), Arcamone et al.
patent: 4035566 (1977-07-01), Modest et al.
patent: 4039633 (1977-08-01), Zelinski
patent: 4039663 (1977-08-01), Penco et al.
patent: 4039736 (1977-08-01), Bradner et al.
patent: 4046878 (1977-09-01), Patelli et al.
patent: 4058519 (1977-11-01), Arcamore et al.
patent: 4067969 (1978-01-01), Penco et al.
patent: 4075328 (1978-02-01), Ducep et al.
patent: 4109076 (1978-08-01), Henry et al.
patent: 4109079 (1978-08-01), Kawahara et al.
patent: 4177264 (1979-12-01), Wu et al.
patent: 4250303 (1981-02-01), Wu et al.
patent: 4296105 (1981-10-01), Baurain et al.
patent: 4325947 (1982-04-01), Penco et al.
patent: 4327087 (1982-04-01), Rosenkrantz et al.
patent: 4438105 (1984-03-01), Sarato et al.
patent: 4537593 (1985-08-01), Alchas
patent: 4564054 (1986-01-01), Gustavsson
patent: 4576211 (1986-03-01), Valentini et al.
patent: 4588403 (1986-05-01), Weiss et al.
patent: 4675311 (1987-06-01), Gatti et al.
patent: 4746516 (1988-05-01), Moro et al.
patent: 4786281 (1988-11-01), Valentini et al.
patent: 4946831 (1990-08-01), Gatti et al.
Arcamone et al, "Structure and Physicochemical Properties", Internation Symposium on Adriamycin (1972) pp. 9-22.
Benvenuto et al, American Journal of Hospital Pharmacy, vol. 38 Dec. 1981, pp. 1914-1918.
Beijnen et al, Pharmaceutical Weekblad Scientific Editor, vol. 7 (1985) pp. 109-116.
Wasserman et al, International Journal of Pharmaceuticals vol. 19 (1983) pp. 73-78.
Bosanquet, Cancer Chemother Pharmacol. (1986) vol. 17 pp. 1-10.
Electrochemical Properties of Adriamycin Adsorbed on a Mercury Electrode Surface Bull. Chem. Soc. Japan, Sep., 1984; vol. 57, pp. 2383-2390; Kenji Kano, Tomonori Konse, Naomi Nishimura and Tanekazu Kubota.
The Effects of the pH and the Termperature on the Oxidation-reduction Properties of Adriamycin Adsorbed on a Mercury Electrode Surface Bull. Chem. Soc. Japan, Feb. 1985; vol. 58, pp. 424-428; Kenji Kano, Tomonori Konse, and Tanekazu Kubota.
American Journal of Hospital Pharmacy, vol. 38, Dec. 1981, pp. 1914-1918, J. Benvenuto, et al., "Stability and Compatibility of Antitumor Agents in Glass and Plastic Containers".
Rote Liste, 1984, Preparation No. 85 031 (with English translation).
H. Bohme, et al., "Europaisches Arzneibuch III," 1979, p. 654 (with English translation).
The Interpharm International Dictionary of Biotechnology and Pharmaceutical Manufacturing, edited by Dean E. Synder, Publisher Buffalo Grove, IL: Interpharm Press, Inc., 1992.
Merck Index, 10.sup.th edition 1983, p. 499, entry 3,435.
Bosanquet, "Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays", Cancer Chemotherapy and Pharmacology, vol. 17, 1986, pp. 1-10.
Rolf Kaltofen, Joachim Ziemann et al., Tabellenbuch Chemie, 12.sup.th edition, pp. 172, 181.
Yuksel, "Determination of Ceftriaxone in Aqueous Humour and Serum Samples by Differrential-pulse Adsorptive Stripping Voltammetry", Analyst, vol. 119, 1994, pp. 1575-1577.
Falbe et al., Rompp Chemie Lexikon, 9.sup.th edition, Georg Thieme Verlag Stuttgart, New York, 1992, "Buffers", pp. 3677-3678.
Mortimer, Chemie, 3.sup.rd edition, Georg Thieme Verlag Stuttgart, New York, 1980, pp. 490-494.
Tan, C. et al., Daunomycin, an Anti-Tumor Antibiotic, in the Treatment of Neoplastic Disease, Mar. 1967, Cancer 20:333-353.
Samuels, L.D. et al., "Daunorubicin Therapy in Advanced Neuroblastoma", Apr. 1971, Cancer 27:831-834.
Miller, A.A. and Schmidt, C.G., "Clinical Pharmacology and Toxocology of 4.increment.-O-tetrahydropyranyladriamycin", Mar. 1, 1987, Cancer Research 47:1461-1465.
Rozencweig, M. et al., "Preliminary Experience with Marcellomycin: Pre-Clinical and Clinical Aspects" p. 5499-561.
Arcamone et al. (1969), "Adriamycin, 14-Hydroxydaunomycin, a New Antitumor Antibiotic from S. Peucetius Var. Caesius," Biotechnology and Bioengineering, vol. XI, pp. 1101-1110.
Despois et al. (1967), "Isolement D'un Nouvel Antibiotique Doue D'Activite Antitumorale: La Rubidomycine (13.057 R.P.) Identite De La Rubidomycine et de La Daunomycine," Path. Biol., vol. 15, pp. 887-891.
Lokich et al. (1983), "Constant Infusion Schedule for Adrimycin: A Phase I-II Clinical Trial of a 30-Day Schedule by Ambulatory Pump Delivery System," J. Clinical Oncology, vol. 1, pp. 24-28.
Wasserman and Bundgaard (1983), "Kinetics of the Acid-Catalyzed Hydrolysis of Doxorubicin," International J. Pharmaceutics, vol. 14, pp. 73-78.
Merck Index (1996), Mitoxantrone, 12th Edition, Entry 6303, p. 1064.
Martindale (1989), Mitotone, The Pharmaceutical Press, 29th Edition, London, Entry 1852-x, pp. 643-645.
ABPI Data Sheet Compendium, 1994-1995, "Novantron Injection," Lederle Laboratories, pp. 752-754.
Geigy Scientific Tables, vol. 3, Physical Chemistry Composition of Blood Hematology Somatometric Data, 8th revised and enlarged edition, Edited by C. Lentner, pp. 54-60.
Chemical Abstracts, vol. 92 (1980), 99512 c.
Chemical Abstracts, vol. 94 (1981), 214489f.
Chemical Abstracts, vol. 99 (1983), 146022z.
Chemical Abstracts, vol. 101 (1984), 122451x.
Chemical Abstracts, vol. 102 (1985), 209266k.
Chemical Abstracts, vol. 104 (1986), 39716d.
Arzneimittel-Forschung, vol. 17 (1967), pp. 934-939.
The Merck Index (1983) p. 3436.
Pharmaceutisch Weekblad, Scientific Edition, vol. 7, Jun. 21, 198 pp. 109-116.
Pharmaceutisch Weekbald, Scientific Edition, vol. 8, Apr. 25, 1986 pp. 109-133.
Journal of Chromatography 299 (1984), pp. 489-494.
Patent Abstracts of Japan (1956), 92212.
Martindale, The Extra Pharmacopoeia (1982), pp. 205-208.
Nor. Pharm. Acta, 45, 61-67 (1983).
J. Pharm. Biomed Anal., 2, 297-303 (1984).
American Journal of Hospital Pharmacy, vol. 38, pp. 483-486, Apr., 1981, G. K. Poochikian, et al., "Stability of Anthracycline Antitumor Agents in Four Infusion Fluids".
International Journal of Pharmaceutics, vol. 23, No. 1, pp. 1-11, Jan., 1985, M. J. H. Janssen, et al., "Doxorubicin Decomposition on Storage. Effect of pH, Type of Buffer and Liposome Encapsulation".
The United States Pharmacopeia, Twentieth revision, p. 266, Jul. 1, 1980.
Chemical Abstracts, vol. 88, p. 396, No. 197, p. 396, No. 197526X, 1978, T. Kaniewska, "Study of the Decomposition of Adriamycin".
Journal of Pharmaceutical Sciences, vol. 67, No. 6, pp. 782-785, Jun., 1978, S. Eksborg, "Extraction of Daunorubicin and Doxorubicin and Their Hydroxyl Metabolites: Self-Association in Aqueous Solution".
Journal of Pharmaceutical Sciences, vol. 73, No. 6, pp. 766-770, M. Memozzi, et al., "Self-Association of Doxorubicin and Related Compounds in Aqueous Solution".
International Symposium on Adriamycin, pp. 9-22, 1972, F. Arcamone, et al., "Structure and Physicochemical Properties of Adriamycin (Doxorubicin)".
Journal of Pharmaceutical and Biomedical Analysis, vol. 2, No. 2, pp. 297-303, 1984, S. Eksborg, et al., "Liquid Chromatography in Anticancer Drug Research with Special Reference to Anthraquinone Glycosides".
American Journal of Intravenous Therapy and Clinical Nutrition, vol. 8, No. 4, pp. 15-18, 1981, D. Ketchman, et al., "Cost Benefit and Stability Study of Doxorubicin Following Reconstitution".
Analytical Profiles of Drug Substances, vol. 9, pp. 245-274, 1980, A. Vigevani, et al., "Doxorubicin".
The Korean Pharmacopeia, 4 pages, 1977, Section "Injections".
The Guidelines for Examination for Each Industrial Field, Chapter "Medicament", 4 pages.
International Journal of Pharmaceutics, vol. 14, pp. 73-78, 1983, K. Wasserman, et al., Kinetics of the Acid-Catalyzed Hy
Bottoni Giuseppe
Confalonieri Carlo
De Ponti Roberto
Gambini Luciano
Gatti Gaetano
Peselev Elli
Pharmacia & Upjohn Company
LandOfFree
Injectable ready-to-use solutions containing an antitumor anthra does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injectable ready-to-use solutions containing an antitumor anthra, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable ready-to-use solutions containing an antitumor anthra will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-581261